Curexo FY2025 shareholder letter, medical-robot division growth and export diversification

The FY2025 shareholder letter attributes the record result to export-country diversification into Japan, Malaysia, Indonesia, Ukraine, Pakistan and Taiwan, states that medical-robot division revenue rose 88 per cent year on year, and confirms Korean MFDS approval of CUVIS-joint for the hip indication in October 2025. A vendor self-disclosure.

Supporting location IR > 전자공고, FY2025 CEO shareholder letter

No current answer cites this record.